Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 2 21:09 ET

The wave of AI in Medical is sweeping: the potential of the macromolecule new drug market is highlighted and imaging products are "going overseas" into Emerging Markets | Focus

① Some executives from pharmaceutical companies have stated that "currently, the discovery of small molecule drugs is very challenging; finding potential molecules and structures is already quite difficult, while there is still significant potential in the discovery and design of large molecule new drugs." ② Currently, the application maturity of AI technology in the imaging field is relatively high, and relevant manufacturers have revealed that the market potential for AI imaging large models in Belt and Road Initiative Concept countries is quite extensive.

cls.cnFeb 26 20:37 ET

The revenue contribution from new products is significant, coupled with the increased volume of artificial heart valves, Beijing Balance Medical Technology Co., Ltd. saw a net profit growth of over two times in Q4 of last year.

① In 2024, the company's revenue from artificial biological heart valves increased by 75.23% year-on-year. In terms of R&D investment, the company's R&D expenses in 2024 increased by 56.14% year-on-year, accounting for 30.68% of revenue; ② The registration of the company's innovative product "transcatheter valve-in-valve system" will be completed soon.

cls.cnFeb 25 07:45 ET

The China Academy of Information and Communications Technology has launched a special test for AI glasses, which are expected to see explosive growth.

① The China Academy of Information and Communications Technology (CAICT) Teher Terminal Laboratory, in collaboration with S-Dream Lab, tested the RayBan-Meta Wayfarer smart glasses, aiming to provide reference evaluation Indicators for the Asia Vets Industry. ② According to WellsennXR, the Global sales volume of AI smart glasses in 2024 is projected at 2.34 million units, with a forecast of 5.5 million units by 2025 (year-on-year +135%).

cls.cnFeb 19 19:03 ET

Shanghai Haohai Biological Technology's net profit growth is weak in 2024, and the Industry is facing a period of performance pain.

① In terms of quarterly performance, Shanghai Haohai Biological Technology achieved a net income of 79.27 million yuan in the fourth quarter, a year-on-year decrease of 11.26% and a quarter-on-quarter decrease of 24.93%. ② The "Shanghai Haohai Biological Technology International Pharmaceutical Research and Development and Industrialization Project" has partially been put into use, and the production capacity for businesses like hyaluronic acid will gradually be released.

cls.cnFeb 19 08:00 ET

Another "miracle drug for myopia" application has been accepted, will Shenyang Xingqi Pharmaceutical's "star product" be impacted? | Quick announcement review

①The application for marketing authorization of HR19034 eye drops under Jiangsu Hengrui Pharmaceuticals has been accepted by the National Medical Products Administration, challenging the exclusive position of Shenyang Xingqi Pharmaceutical. ② The atropine sulfate eye drops suitable for myopia in adolescents under several pharmaceutical companies have all entered phase 3 clinical trials.

cls.cnFeb 17 11:21 ET